Related Experiment Video
Updated: Aug 5, 2026
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
Published on: December 3, 2013
Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation
Nada A Almarghalani1,2,3, Magdah A Ganash1, Mona G Alharbi1
1Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Abstract:
Cancer remains a major global health challenge, with conventional therapies often limited by toxicity and insufficient efficacy. Oncolytic virotherapy has emerged as a promising immunotherapeutic approach, utilizing genetically engineered viruses to selectively target and destroy cancer cells while stimulating anti-tumor immune responses. Among various oncolytic viruses, adenoviruses (HAdVs) have been extensively studied due to their ability to be genetically modified for enhanced tumor selectivity and immunogenicity. This review explores the mechanisms by which adenovirus vectors function as cancer immunotherapies, detailing their genetic modifications to improve tumor targeting, replication, and immune activation. Additionally, we highlight key clinical trials that have evaluated adenovirus-based therapies in different cancer types, emphasizing their efficacy, safety, and potential for future therapeutic applications.
Insights
Oncolytic virotherapy uses engineered adenoviruses (HAdVs) to target and destroy cancer cells, stimulating immune responses. This review details HAdV mechanisms, genetic modifications, and clinical trials for cancer immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Cancer poses a significant global health challenge, with conventional treatments facing limitations in efficacy and safety.
- Oncolytic virotherapy presents a promising immunotherapeutic strategy, employing genetically modified viruses to selectively eliminate cancer cells and activate anti-tumor immunity.
- Adenoviruses (HAdVs) are extensively researched for oncolytic virotherapy due to their genetic modifiability for enhanced tumor specificity and immunogenicity.
Purpose of the Study:
- To review the mechanisms of adenovirus vectors in cancer immunotherapy.
- To detail genetic modifications aimed at improving tumor targeting, replication, and immune activation of adenoviruses.
- To highlight clinical trials evaluating adenovirus-based cancer therapies, focusing on efficacy, safety, and future potential.
Main Methods:
- Review of scientific literature on adenovirus-based cancer immunotherapy.
- Analysis of genetic engineering strategies for enhancing adenovirus oncolytic properties.
- Summarization of findings from key clinical trials involving adenovirus therapies for various cancers.
Main Results:
- Adenovirus vectors can be genetically modified to achieve selective tumor targeting and replication.
- These modifications enhance the induction of anti-tumor immune responses.
- Clinical trials demonstrate the safety and potential efficacy of adenovirus-based therapies across different cancer types.
Conclusions:
- Adenovirus vectors are a viable platform for developing novel cancer immunotherapies.
- Further research and clinical evaluation are warranted to optimize adenovirus-based treatments for improved patient outcomes.
- Adenovirus oncolytic virotherapy holds significant promise for future cancer treatment strategies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:29Microorganisms in Medicine and Therapeutics